TY - JOUR AU - Sun, Yuzhu AU - Wang, Xiaofang AU - Zhang, Aoxue AU - Zhang, Bao AU - Shao, Liwei AU - Liu, Yue AU - Wang, Haiting AU - Luo, Wanhe AU - Chen, Dongmei AU - Xie, Shuyu PY - 2021/01/11 Y2 - 2024/03/28 TI - Pharmacokinetics of oxfendazole nanosuspension in sheep JF - The Thai Journal of Veterinary Medicine JA - TJVM VL - 51 IS - 1 SE - Original Articles DO - UR - https://he01.tci-thaijo.org/index.php/tjvm/article/view/247171 SP - 29-33 AB - <p><span class="fontstyle0">The pharmacokinetics of our previous prepared oxfendazole nanosuspension was studied in sheep to understand<br>its enhancement of bioavailability. Ten sheep were randomly divided into two groups, each of which received a singledose (5mg/kg) oral oxfendazole nanosuspension and oxfendazole granules. After intragastric administration,<br>oxfendazole rapidly reached peak concentrations of 11.25 μg/mL and 5.50 µg/mL at 5.6 h and 6.6 h in the<br>nanosuspension group and granules group and the concentrations gradually reduced to below the detection limit at 96<br>h and 72h, respectively. The main pharmacokinetic parameters of oxfendazole after administration to the sheep: The<br>T</span><span class="fontstyle0">max</span><span class="fontstyle0">, C</span><span class="fontstyle0">max</span><span class="fontstyle0">, AUC</span><span class="fontstyle0">last</span><span class="fontstyle0">, MRT</span><span class="fontstyle0">last</span><span class="fontstyle0">, T</span><span class="fontstyle0">1/2 </span><span class="fontstyle0">and Ke of in nanosuspension were 5.6 h, 11.26 µg/mL, 179.22 µg*h/mL, 17.82 h, 87.22<br>h and 0.012 1/h, respectively, while the these main pharmacokinetic parameters in the OFZ granules group were 6.6 h,<br>5.50 µg/mL, 105.28 µg*h/mL, 16.55 h, 35.04 h, and 0.020 1/h, respectively. Compared with the granules group, the C</span><span class="fontstyle0">max<br></span><span class="fontstyle0">and AUC</span><span class="fontstyle0">last </span><span class="fontstyle0">of the nanosuspension group were increased by 2.05 and 1.70 times, respectively, and the C</span><span class="fontstyle0">max </span><span class="fontstyle0">and AUC</span><span class="fontstyle0">last<br></span><span class="fontstyle0">of the total active compound in the nanosuspension group were increased by 1.85 times and 1.71 times, respectively.<br>These results suggest that the oxfendazole suspension might be an effective and promising formulation for use in sheep.</span> </p> ER -